Impact of perineural invasion on survival in node negative colon cancer

References

• No authors listed. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995; 345:939-44; PMID: 7715291; https://doi.org/10.1016/S0140-6736(95)90696-7
   PubMedGoogle Scholar
• O'Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ, Wieand HS. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15:246-50; PMID: 8996149; https://doi.org/10.1200/JCO.1997.15.1.246
   PubMed Web of Science ®Google Scholar
• Yothers G, O'Connell MJ, Allegra CJ, Kuebler JP, Colangelo LH, Petrelli NJ, Wolmark N. Oxaliplatin as adjuvant therapy for colon cancer: Updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 2011; 29:3768-74; PMID: 21859995; https://doi.org/10.1200/JCO.2011.36.4539
   PubMed Web of Science ®Google Scholar
• Wolmark N, Fisher B, Rockette H, Redmond C, Wickerham DL, Fisher ER, Jones J, Glass A, Lerner H, Lawrence W, et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: Results from NSABP protocol C-01. J Natl Cancer Inst 1988; 80:30-6; PMID: 3276901; https://doi.org/10.1093/jnci/80.1.30
   PubMed Web of Science ®Google Scholar
• Wolmark N, Wieand HS, Hyams DM, Colangelo L, Dimitrov NV, Romond EH, Wexler M, Prager D, Cruz AB Jr, Gordon PH, et al. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst 2000; 92:388-96; PMID: 10699069; https://doi.org/10.1093/jnci/92.5.388
   PubMed Web of Science ®Google Scholar
• Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, et al. Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350:2343-51; PMID: 15175436; https://doi.org/10.1056/NEJMoa032709
   PubMed Web of Science ®Google Scholar
• Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27:3109-16; PMID: 19451431; https://doi.org/10.1200/JCO.2008.20.6771
   PubMed Web of Science ®Google Scholar
• Grem JL, Allegra CJ. Toxicity of levamisole and 5-fluorouracil in human colon carcinoma cells. J Natl Cancer Inst 1989; 81:1413-17; PMID: 2778828; https://doi.org/10.1093/jnci/81.18.1413
   PubMed Web of Science ®Google Scholar
• Haller DG, Catalano PJ, Macdonald JS, O'Rourke MA, Frontiera MS, Jackson DV, Mayer RJ. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: Final report of Intergroup 0089. J Clin Oncol 2005; 23:8671-8; PMID: 16314627; https://doi.org/10.1200/JCO.2004.00.5686
   PubMed Web of Science ®Google Scholar
• Chapuis PH, Dent OF, Fisher R, Newland RC, Pheils MT, Smyth E, Colquhoun K. A multivariate analysis of clinical and pathological variables in prognosis after resection of large bowel cancer. Br J Surg 1985; 72:698-702; PMID: 4041728; https://doi.org/10.1002/bjs.1800720909
   PubMed Web of Science ®Google Scholar
• Quah HM, Chou JF, Gonen M, Shia J, Schrag D, Landmann RG, Guillem JG, Paty PB, Temple LK, Wong WD, et al. Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis Colon Rectum 2008; 51:503-7; PMID: 18322753; https://doi.org/10.1007/s10350-008-9246-z
   PubMed Web of Science ®Google Scholar
• Faivre-Finn C, Bouvier-Benhamiche AM, Phelip JM, Manfredi S, Dancourt V, Faivre J. Colon cancer in France: Evidence for improvement in management and survival. Gut 2002; 51:60-4; PMID: 12077093; https://doi.org/10.1136/gut.51.1.60
   PubMed Web of Science ®Google Scholar
• Petersen VC, Baxter KJ, Love SB, Shepherd NA. Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer. Gut 2002; 51:65-9; PMID: 12077094; https://doi.org/10.1136/gut.51.1.65
   PubMed Web of Science ®Google Scholar
• Chen HS, Sheen-Chen SM. Obstruction and perforation in colorectal adenocarcinoma: An analysis of prognosis and current trends. Surgery 2000; 127:370-6; PMID: 10776426; https://doi.org/10.1067/msy.2000.104674
   PubMed Web of Science ®Google Scholar
• Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much?. J Clin Oncol 2004; 22:1797-806; PMID: 15067028; https://doi.org/10.1200/JCO.2004.09.059
   PubMed Web of Science ®Google Scholar
• Kumar A, Kennecke HF, Renouf DJ, Lim HJ, Gill S, Woods R, Speers C, Cheung WY. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer. Cancer 2015; 121:527-34; PMID: 25332117; https://doi.org/10.1002/cncr.29072
   PubMed Web of Science ®Google Scholar
• O'Connor ES, Greenblatt DY, LoConte NK, Gangnon RE, Liou JI, Heise CP, Smith MA. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol 2011; 29:3381-8; PMID: 21788561; https://doi.org/10.1200/JCO.2010.34.3426
   PubMed Web of Science ®Google Scholar
• Cakar B, Varol U, Junushova B, Muslu U, Gursoy Oner P, Gokhan Surmeli Z, Cirak Y, Karaca B, Sezgin C, Karabulut B, et al. Evaluation of the efficacy of adjuvant chemotherapy in patients with high-risk stage II colon cancer. J BUON 2013; 18:372-6; PMID: 23818348.
   PubMed Web of Science ®Google Scholar
• Nikberg M, Chabok A, Letocha H, Kindler C, Glimelius B, Smedh K. Lymphovascular and perineural invasion in stage II rectal cancer: A report from the Swedish colorectal cancer registry. Acta Oncol 2016; 55(12):1418-1424; PMID: 27732105; https://doi.org/10.1080/0284186X.2016.1230274
   PubMed Web of Science ®Google Scholar
• Huh JW, Lee JH, Kim HR, Kim YJ. Prognostic significance of lymphovascular or perineural invasion in patients with locally advanced colorectal cancer. Am J Surg 2013; 206:758-63; PMID: 23835209; https://doi.org/10.1016/j.amjsurg.2013.02.010
   PubMed Web of Science ®Google Scholar
• Liebig C, Ayala G, Wilks J, Verstovsek G, Liu H, Agarwal N, Berger DH, Albo D. Perineural invasion is an independent predictor of outcome in colorectal cancer. J Clin Oncol 2009; 27:5131-7; PMID: 19738119; https://doi.org/10.1200/JCO.2009.22.4949
   PubMed Web of Science ®Google Scholar
• Fujita S, Nakanisi Y, Taniguchi H, Yamamoto S, Akasu T, Moriya Y, Shimoda T. Cancer invasion to Auerbach's plexus is an important prognostic factor in patients with pT3-pT4 colorectal cancer. Dis Colon Rectum 2007; 50:1860-6; PMID: 17899273; https://doi.org/10.1007/s10350-007-9072-8
   PubMed Web of Science ®Google Scholar
• Yang Y, Huang X, Sun J, Gao P, Song Y, Chen X, Zhao J, Wang Z. Prognostic value of perineural invasion in colorectal cancer: A meta-analysis. J Gastrointest Surg 2015; 19:1113-22; PMID: 25663635; https://doi.org/10.1007/s11605-015-2761-z
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Center (NCCN). NCCN Clinical Practice Guidelines in Oncology: Colon Cancer Version 2.2016. 2016; http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
   Google Scholar
• Suzuki T, Suwa K, Ogawa M, Eto K, Kawahara H, Fujita T, Ikegami M, Yanaga K. Adjuvant chemotherapy for the perineural invasion of colorectal cancer. J Surg Res 2015; 199:84-9; PMID: 25935467; https://doi.org/10.1016/j.jss.2015.03.101
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40:373-83; PMID: 3558716; https://doi.org/10.1016/0021-9681(87)90171-8
   PubMedGoogle Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45:613-19; PMID: 1607900; https://doi.org/10.1016/0895-4356(92)90133-8
   PubMed Web of Science ®Google Scholar